During the secondary analysis, the less conservative but clinically meaningful criterion of steady response (defined as being a fifty% or more reduction in MADRS from baseline for 2 weeks) was used. Of the patients who reached secure response, 25.eight% in the esketamine group and fifty seven.6% from the placebo group https://jamesn260fil9.ourabilitywiki.com/user